Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003656 · ClinicalTrials.gov registry record · Phase 2
Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer
A Phase 2 study of Kidney Cancer, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 2
- Study locations
NCT00003656: Completed Phase 2 study of Kidney Cancer, sponsored by Weill Medical College of Cornell University.
NCT00003656 is a Phase 2 study of Kidney Cancer that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 26 participants, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003656, a Phase 2 study of Kidney Cancer, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Tretinoin may help kidney cancer cells develop into normal cells. Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of liposomal tretinoin plus interferon alfa in treating patients who have metastatic kidney cancer.
Conditions Studied
Interventions
- BIOLOGICAL recombinant interferon alfa
- DRUG tretinoin liposome
Study Locations (2)
New York
- New York Weill Cornell Cancer Center at Cornell University - New York
- Herbert Irving Comprehensive Cancer Center at Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 1999-01 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
What the finished NCT00003656 record still lists
NCT00003656 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 2 interventions - of which recombinant interferon alfa is the first listed.
NCT00003656 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00003656 about?
NCT00003656 is a clinical study titled "Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer". RATIONALE: Tretinoin may help kidney cancer cells develop into normal cells. Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of liposomal tretinoin plus interferon alfa in treating patients who have metastatic kidney cancer.
What is the current status of trial NCT00003656?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 1999-01. Estimated completion is 2008-05.
What conditions does trial NCT00003656 study?
This clinical trial studies the following conditions: Kidney Cancer.
What interventions are being tested in trial NCT00003656?
The interventions under investigation include: recombinant interferon alfa (BIOLOGICAL), tretinoin liposome (DRUG).
Who is sponsoring clinical trial NCT00003656?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003656 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003656's enrollment target sits among peer trials
26 43rd of 60 higher than 17 of 60 other Kidney Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
NSAID Use After Robotic Partial Nephrectomy
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia